Frost & Sullivan releases 'Research Report on the Innovative Small Molecule Targeted Drug Market'

On June 15, 2022, the globally renowned growth consulting firm Frost & Sullivan released a 'Research Report on the Market for Innovative Small Molecule Targeted Drugs'. The report provides an exhaustive analysis of the market overview, driving factors, and future development trends of the small molecule targeted drug markets globally and in China. It focuses on sorting out a series of popular anti-tumor target tracks including EGFR, NTRK, HER2, etc. In the Chinese pharmaceutical market, the sales of anti-tumor drugs have been showing a steady growth trend in recent years. The market size reached RMB 197.5 billion in 2020, with a compound annual growth rate of 12.1% over the past five years. Currently, global anti-tumor drugs are dominated by targeted drugs, accounting for more than 60% of the overall market, with immunotherapy drugs exceeding chemotherapy drugs in terms of market share, reaching 23.4%. It is estimated that by 2030, the share of targeted drugs will reach 42.2%. In China, driven by favorable policies, new drug launches and improved patient affordability, targeted therapy will account for about half of the total market by 2030. Small molecule targeted drugs are widely used in cancer treatment and are an indispensable part of the future tumor treatment technology landscape.